C4 Imaging develops innovative medical devices that enable clinicians to personalize patient treatment through accurate image-guided procedures. The company’s core proprietary technology, C4, is a unique magnetic resonance imaging (MRI) agent that has been encapsulated within an implantable, biocompatible shell. C4 Imaging’s first product is the Sirius™ MRI Marker, which will be used to facilitate seed localization during the treatment of prostate cancer. The Sirius™ MRI Marker will allow physicians to accurately locate seeds within the complicated anatomy of the prostate and the surrounding critical structures, utilizing a single post-implant MR imaging procedure. C4 Imaging’s goal is to improve quality assurance by allowing post-implant seed localization to be performed with MRI alone, eliminating the need for computed tomography in assessment of prostate brachytherapy.
Looking for a particular C4 Imaging employee's phone or email?
The C4 Imaging annual revenue was $7 million in 2026.
Andrew Bright is the President and Board member of C4 Imaging.
2 people are employed at C4 Imaging.
C4 Imaging is based in Bellaire, Texas.
The NAICS codes for C4 Imaging are [62151, 333, 6215, 621, 62, 33].
The SIC codes for C4 Imaging are [80, 807].